Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5052W HIGH $9.95
Volume
1.47 M
Value Traded
2.26 M
Short % Float
15.73%
-15.38%Week
-44%1 Month
-38.4%3 Month
-47.8%6 Month
-76.57%5 Year
-66.31%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
142.75 M
EPS (TTM)
-0.14
P/E Ratio
-
Ent. Value
24.43 M
Total Shares
92.73 M
Float Shares
91.12 M
Insiders
1.71%
Institutions
40.16%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AVXL Catalyst Timeline
Dated clinical, regulatory and corporate events for Anavex Life Sciences Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Anavex Life Sciences Corp.
811Total events
9Upcoming
146Tier-1 (high impact)
2010 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Corporate ApprovalCorporate
Stockholders elect all six director nominees at 2026 Annual Meeting
▲Corporate ApprovalCorporate
ISS recommends stockholders vote FOR all six Anavex director nominees
▲Timing GuidancePresentation
ISS recommended stockholders vote FOR all six Anavex director nominees
●R&D DayPresentation
Anavex to host investor conference call to discuss clinical development strategy
▲Quarterly UpdateCorporate
Anavex regained NASDAQ listing compliance after filing outstanding Form 10-Qs
▲Other Regulator MilestoneEx-US Regulatory
Anavex regained compliance with NASDAQ listing rules
▲Quarterly UpdateCorporate
Anavex filed outstanding Form 10-Q filings for Q2 and Q3 fiscal 2026
●IND SubmissionANAVEX®2-73FiledIND
Submitted all data from Alzheimer's disease clinical trials to newly opened Alzheimer's IND
Alzheimer's diseasesource ↗
●Timing GuidancePresentation
Plans to file outstanding Form 10-Q filings for Q2 and Q3 FY2026 in near term
◆Type B MeetingANAVEX®2-73FiledFDA Meeting
Formal meeting request submitted to FDA to discuss adding pediatric patients to Rett syndrome Phase 3 study
Rett syndromesource ↗
▲Trial InitiationANAVEX®2-73FiledTrial
First participant visit in ADME study completed
Alzheimer's diseasesource ↗
▲FDA Filing AcceptedANAVEX®2-73FiledRegulatory Filing
Submitted all data from Alzheimer's disease clinical trials to newly opened Alzheimer's IND
Alzheimer's diseasesource ↗
●Quarterly UpdateCorporate
Released preliminary second fiscal quarter financial results and business update
●Runway Guidance UpdateCorporate
Cash runway guidance: funds operations into mid-to-late fiscal 2028
▲FDA Feedback ReceivedFDA Meeting
Aligned with FDA on Phase 3 protocol for Rett syndrome (adults)
Rett syndromesource ↗
●Trial InitiationTrial
Initiation of ADME study anticipated in Q3 2026
early Alzheimer's diseasesource ↗
◆Trial InitiationblarcamesineFiledTrial
ADME study expected to begin
early Alzheimer's diseasesource ↗
●Oral PresentationblarcamesineFiledPresentation
Participation in AAIC conference in London
Alzheimer's diseasesource ↗
▲EU MAA SubmissionANAVEX®2-73FiledEx-US Regulatory
Received Scientific Advice from EMA for Phase 3 study design
Alzheimer's diseasesource ↗
●Quarterly UpdateCorporate
Company expects to file Form 12b-25 to extend Q1 2026 10-Q filing date
◆Oral PresentationPresentation
Presentation at 25th Annual Needham Virtual Healthcare Conference
◆Timing GuidanceANAVEX3-71DiscontinuedPresentation
Topline data from Phase 2 ANAVEX 3-71 trial expected in calendar Q2 2026
Alzheimer's diseasesource ↗
◆Timing GuidanceblarcamesineFiledPresentation
Topline data from Phase 2 Parkinson's disease trial expected in calendar Q2 2026
Parkinson's diseasesource ↗
▼Program DiscontinuationANAVEX3-71DiscontinuedCorporate
Completion of ANAVEX 3-71 clinical trial for schizophrenia
schizophreniasource ↗
▼CHMP Negative OpinionblarcamesineFiledEx-US Regulatory
CHMP negative opinion led to withdrawal of EU marketing authorization application for blarcamesine in early Alzheimer's disease
early Alzheimer's diseasesource ↗
▼EU MAA SubmissionblarcamesineFiledEx-US Regulatory
Withdrawal of EU marketing authorization application for blarcamesine in early Alzheimer's disease
early Alzheimer's diseasesource ↗
◆FDA Feedback ReceivedblarcamesineFiledFDA Meeting
Additional data submitted to FDA to discuss potential NDA pathway for blarcamesine in early Alzheimer's disease
early Alzheimer's diseasesource ↗
◆Other Regulator MilestoneblarcamesineFiledEx-US Regulatory
Regulatory engagement with EU authorities for blarcamesine in Parkinson's disease
Parkinson's diseasesource ↗
▼CHMP Negative OpinionblarcamesineFiledEx-US Regulatory
CHMP indicated it would not issue a positive opinion for blarcamesine MAA
early Alzheimer's diseasesource ↗
▼EU MAA SubmissionblarcamesineFiledEx-US Regulatory
Withdrawal of MAA for blarcamesine in EU
early Alzheimer's diseasesource ↗
▲Oral PresentationblarcamesineFiledPresentation
Oral presentation at AD/PD 2026 Conference on blarcamesine brain volume preservation data
early Alzheimer's diseasesource ↗
▲Full ResultsblarcamesineFiledClinical Data
Long-term clinical data showing 77.4 weeks time saved vs ADNI1 control after 144 weeks treatment
early Alzheimer's diseasesource ↗
▲PublicationPresentation
New peer-reviewed study published in PNAS Nexus supporting autophagy failure hypothesis in Alzheimer's disease
Alzheimer's diseasesource ↗
▲Oral PresentationblarcamesineFiledPresentation
Presentation of blarcamesine data in alpha-synuclein Parkinson's model at AD/PD 2026 Conference
Parkinson's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How AVXL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | ANAVEX®2-73 (blarcamesine) | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$55M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 44%
Micro Cap(rank 290 of 658)
Percentile Rank
Anavex Life Sciences Corp. faces pipeline headwinds (38/100), with $443M risk-adjusted pipeline value, led by High dose ANAVEX2-73 in Parkinson Disease Dementia (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| High dose ANAVEX2-73 Small moleculeCompletedNCT03758924 | Rett Syndrome | Phase 3 | COMPLETED | 64 | Oct 30, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every AVXL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| blarcamesine Fast TrackOrphanRare Pediatric | early Alzheimer's disease | Phase 2b/3 | 2026-03-23 | 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatment; R² increasing by 78% for ADAS-Cog13 (from R²=0.23 to R²=0.41)Read More | Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MISSLING CHRISTOPHER UDirector, Officer (President and CEO) | Option | 187,500 1,655,213 held | $5.04 | 09/11/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in AVXL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 0.3 % (-25 %) | 1.35 M | 521.30 K |
AVXL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AVXL ranks across every disease it competes in
Competitive Position is a premium feature
See how AVXL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAVXL News
AVXLAnavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
Anavex Life Sciences Corp. announced that stockholders elected all six director nominees during its 2026 Annual Meeting. Dr. Jiong Ma, the Independent Chair, expressed gratitude for the trust shown by stockholders and emphasized the board's commitment to governance and strategic execution. The final voting results will be disclosed after certification.
Read more →AVXLLeading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees
Anavex Life Sciences Corp. announced that Institutional Shareholder Services (ISS) recommended stockholders vote 'FOR' all six of its director nominees for the upcoming Annual Meeting. ISS noted the company's strategic direction and board refreshment, asserting that the opposing dissident group did not present a compelling case for change. The Annual Meeting is scheduled for September 24, 2026.
Read more →AVXLAnavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
Anavex Life Sciences Corp. will host an investor call on September 9, 2026, at 4:00 PM ET. The call will feature Interim CEO Terrie Kellmeyer discussing the company's clinical development strategy. Anavex has recently regained compliance with NASDAQ listing rules, indicating a positive financial standing.
Read more →AVXLAnavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Anavex Life Sciences Corp. has confirmed its compliance with Nasdaq Listing Rule 5250(c)(1) after filing its outstanding Form 10-Qs for the second and third fiscal quarters of 2026. This compliance allows the company's stock to continue trading on the Nasdaq Global Select Market under the ticker AVXL. The company focuses on developing treatments for CNS diseases.
Read more →AVXL▲ +14.5%on this news
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Anavex Life Sciences reported its financial results for Q3 2026, highlighting significant progress in its Alzheimer's disease clinical trials and plans for upcoming studies in Rett and Fragile X syndromes. The company has submitted data to the FDA and is advancing regulatory discussions. Financially, Anavex showed a net income of $7.8 million, marking a recovery from previous losses.
Read more →AVXLAnavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
Anavex Life Sciences has mailed a letter to stockholders urging them to vote for all six director nominees in the upcoming Annual Meeting. The nominees possess extensive experience in various fields, including clinical research and financial markets. The meeting is scheduled for September 24, 2026, and stockholders can find more information on the company's dedicated website.
Read more →AVXLAnavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
Anavex Life Sciences has filed definitive proxy materials for its 2026 Annual Meeting, urging stockholders to vote for its six independent director nominees. The company highlights its strategic actions to enhance long-term value, including the appointment of an interim CEO and advancement of its lead candidate, oral blarcamesine, across three CNS indications. In contrast, Anavex criticizes PVG's lack of a clear plan and the inexperience of its nominees.
Read more →AVXL▲ +7.3%on this news· ran to +19% by day 3
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
Anavex Life Sciences Corp. has announced the nomination of two new independent directors, Gautam Patel and Adrian Senderowicz, to enhance its Board ahead of the 2026 Annual Meeting. The company urges stockholders to reject a proxy attempt by PVG Asset Management to gain control. Anavex emphasizes its commitment to advancing its lead candidate for Alzheimer's disease while ensuring stockholder value.
Read more →AVXL▲ +8.4%on this news· ran to +27% by day 3shared move
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
Anavex Life Sciences reported preliminary financial results for Q2 2026, highlighting progress in its clinical programs for Alzheimer's disease, Rett syndrome, and Fragile X syndrome. The company is focused on advancing its lead compound, blarcamesine, and is actively engaging with the FDA on regulatory strategies. Preliminary financials indicate a reduced net loss compared to the previous year, with sufficient cash reserves to fund operations into mid-2028.
Read more →AVXLAnavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Anavex Life Sciences Corp. received a delinquency notification from Nasdaq due to its failure to file Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a plan to regain compliance. Despite this notification, there is no immediate impact on its stock.
Read more →AVXLAnavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief YORK, NY, May 6, 2026 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage
Anavex Life Sciences Corp. has appointed Dr. Terrie Kellmeyer as Interim Chief Executive Officer following the resignation of former CEO Christopher Missling. Dr. Kellmeyer, who has nearly three decades of experience in the pharmaceutical industry, is expected to lead the company's clinical development efforts and enhance its initiatives in treating neurological disorders. The company also announced a delay in filing its Quarterly Report due to regulatory compliance issues, which it plans to address in an upcoming conference call.
Read more →AVXLAnavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
Anavex Life Sciences has identified new scientific evidence linking autism spectrum disorder (ASD) and Alzheimer's disease (AD), highlighting common biological dysfunctions, particularly in autophagy. This research underpins the company's strategic focus on the investigational drug blarcamesine, designed to enhance autophagy, which has shown potential in clinical trials for both conditions. The findings provide a rationale for advancing blarcamesine into pivotal studies, aiming to tackle disease mechanisms that affect both neurodevelopmental and neurodegenerative disorders.
Read more →AVXLAnavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Anavex Life Sciences Corp. will present at the 25th Annual Needham Virtual Healthcare Conference from April 13 to 16, 2026. CEO Christopher U. Missling and his team will discuss the company's advancements in treatments for neurodegenerative and neurodevelopmental disorders, including Alzheimer's and Parkinson's diseases. The presentation is scheduled for April 14 at 1:30 PM ET, with a live audio webcast available.
Read more →AVXLAnavex Life Sciences Provides Comprehensive Regulatory Update
Anavex Life Sciences has provided an update on the regulatory progress of its drug blarcamesine for early Alzheimer's disease, noting ongoing dialogue with the EMA and FDA. The company aims to address points raised during the EU regulatory review while also expanding discussions to include Parkinson's disease and rare diseases like Rett syndrome. Despite the withdrawal of its marketing authorization application in the EU, Anavex is optimistic about future regulatory pathways and continues to gather data to support its development programs.
Read more →AVXL▼ -34.6%on this newsshared move
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Anavex Life Sciences has withdrawn its application for marketing authorization of blarcamesine in the EU for early Alzheimer's disease treatment, following negative feedback from the EMA's CHMP. Despite this setback, Anavex is committed to advancing the drug's development and addressing the concerns raised by the regulatory body. The company aims to gather more data to support future applications.
Read more →AVXL▲ +9.4%on this news· ran to -29% by day 3shared move
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
Anavex Life Sciences Corporation presented new data on its drug blarcamesine at the AD/PD 2026 Conference, highlighting its potential for preserving brain volume in early Alzheimer's disease patients. The data showed a correlation between treatment with blarcamesine and improved clinical outcomes over a long-term period compared to a control group. An emphasis was placed on the drug's oral administration and manageable side effects, which could enhance patient compliance and quality of life. The results support Anavex's precision medicine approach by showing greater benefits for genetically defined patient populations.
Read more →AVXLNew Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
Anavex Life Sciences announced a new study linking autophagy failure to Alzheimer's disease pathology. The research suggests that impaired autophagy precedes amyloid beta and tau aggregation, highlighting the potential for early intervention. The findings support Anavex's drug candidate, blarcamesine, which aims to restore autophagy and address Alzheimer's disease mechanisms.
Read more →AVXLAnavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
Anavex Life Sciences Corp. announced positive new data on blarcamesine during the AD/PD 2026 Conference. The data reveal that blarcamesine can improve motor function and stimulate dopaminergic nerve fiber growth in a new Parkinson's disease model that combines alpha-synuclein accumulation with noradrenergic degeneration. The study presents evidence supporting blarcamesine as a candidate for disease-modifying therapy in Parkinson's disease. Anavex's CEO expressed optimism regarding the drug's potential to advance clinical programs in early-stage Parkinson's treatment.
Read more →AVXLAnavex Life Sciences to Present at the Citizens Life Sciences Conference
Anavex Life Sciences Corp. will present at the Citizens Life Sciences Conference on March 10, 2026. CEO Christopher U Missling will discuss the company's innovative treatments for CNS disorders, including Alzheimer's and Parkinson's diseases. Anavex's lead candidate, ANAVEX®2-73, has shown positive results in multiple clinical trials, indicating its potential effectiveness.
Read more →AVXLAnavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
Anavex Life Sciences Corp. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Christopher U Missling will discuss the company's innovative treatments for CNS disorders, including Alzheimer's and Parkinson's diseases. Anavex's lead drug candidate, ANAVEX®2-73, has completed multiple successful clinical trials.
Read more →About Anavex Life Sciences Corp.
Headquarters630 5TH AVENUE, NEW YORK, NY, 10111
Founded2004
BIOPHARMAWATCH ELITE PLUS
Trade the next AVXL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime